Prophylactic Administration of Surfactant in Extremely Premature Infants

Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (cu...

Full description

Saved in:
Bibliographic Details
Main Authors: Lutz Koch, David Frommhold, Bernd Beedgen, Peter Ruef, Johannes Poeschl
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Critical Care Research and Practice
Online Access:http://dx.doi.org/10.1155/2010/235894
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554365740646400
author Lutz Koch
David Frommhold
Bernd Beedgen
Peter Ruef
Johannes Poeschl
author_facet Lutz Koch
David Frommhold
Bernd Beedgen
Peter Ruef
Johannes Poeschl
author_sort Lutz Koch
collection DOAJ
description Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf0𝑥000𝑎𝑒) within five minutes after birth (prophylactic group, 𝑁=31) with those infants who received surfactant therapy for established RDS (selective group, 𝑁=34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.
format Article
id doaj-art-7916aed201b64e73a0d5cfd7367b5eed
institution Kabale University
issn 2090-1305
2090-1313
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Critical Care Research and Practice
spelling doaj-art-7916aed201b64e73a0d5cfd7367b5eed2025-02-03T05:51:45ZengWileyCritical Care Research and Practice2090-13052090-13132010-01-01201010.1155/2010/235894235894Prophylactic Administration of Surfactant in Extremely Premature InfantsLutz Koch0David Frommhold1Bernd Beedgen2Peter Ruef3Johannes Poeschl4Division of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyObjective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf0𝑥000𝑎𝑒) within five minutes after birth (prophylactic group, 𝑁=31) with those infants who received surfactant therapy for established RDS (selective group, 𝑁=34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.http://dx.doi.org/10.1155/2010/235894
spellingShingle Lutz Koch
David Frommhold
Bernd Beedgen
Peter Ruef
Johannes Poeschl
Prophylactic Administration of Surfactant in Extremely Premature Infants
Critical Care Research and Practice
title Prophylactic Administration of Surfactant in Extremely Premature Infants
title_full Prophylactic Administration of Surfactant in Extremely Premature Infants
title_fullStr Prophylactic Administration of Surfactant in Extremely Premature Infants
title_full_unstemmed Prophylactic Administration of Surfactant in Extremely Premature Infants
title_short Prophylactic Administration of Surfactant in Extremely Premature Infants
title_sort prophylactic administration of surfactant in extremely premature infants
url http://dx.doi.org/10.1155/2010/235894
work_keys_str_mv AT lutzkoch prophylacticadministrationofsurfactantinextremelyprematureinfants
AT davidfrommhold prophylacticadministrationofsurfactantinextremelyprematureinfants
AT berndbeedgen prophylacticadministrationofsurfactantinextremelyprematureinfants
AT peterruef prophylacticadministrationofsurfactantinextremelyprematureinfants
AT johannespoeschl prophylacticadministrationofsurfactantinextremelyprematureinfants